Brandon Folkes, an analyst from H.C. Wainwright, reiterated the Buy rating on Valneva. The associated price target remains the same with $18.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Brandon Folkes has given his Buy rating due to a combination of factors including the recent selloff of Valneva’s stock, which he believes is an overreaction to the FDA’s suspension of IXCHIQ. Despite this setback, the suspension is not expected to significantly impact Valneva’s revenue, as IXCHIQ contributes a small portion of the company’s sales.
Folkes is optimistic about the upcoming data release for VLA15, a Lyme disease vaccine candidate co-developed with Pfizer, which could be a major value driver for the company. The potential for VLA15 to address an unmet medical need and its promising commercial prospects underpin a favorable risk-reward profile for Valneva. Additionally, the partnership with Pfizer reduces Valneva’s financial burden, enhancing the stock’s attractiveness. The current valuation, according to Folkes, does not fully reflect the company’s potential, making it an appealing investment opportunity.
In another report released today, Jefferies also maintained a Buy rating on the stock with a $14.00 price target.